


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,

Washington, D.C. 20231 on May 20, 1999

David Saliwanchik

David R. Saliwanchik, Patent Attorney



INFORMATION DISCLOSURE  
STATEMENT

Patent Application

Docket No. SPO-103

Serial No. 09/142,524

Art Unit: 1646

RECEIVED

AUG 28 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Art Unit : 1646  
Applicant(s) : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino  
Serial No. : 09/142,524  
Filed : September 9, 1998  
For : Peptide-based Immunotherapeutic Agent For Treating Allergic Diseases

Assistant Commissioner for Patents

Washington, D.C. 20231

RECEIVED

JUN 1 1999

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §§1.97 AND 1.98

TECH CENTER 1600/2900

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David Saliwanchik

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRS/la

Enclosures: as stated above